The performance of
Johnson & Johnson (JNJ) has seen considerable fluctuations. Despite a 5.5% increase post the last Earnings Report, Insider Stock disposals indicate possible caution. Johnson & Johnson plans to acquire
Proteologix for $850 million to lead in Atopic Dermatitis Treatment, whilst also facing numerous legal battles over allegations linking their baby powder to ovarian cancer; this has resulted in settlements amounting to $6.5 billion. Nevertheless, the company received a reaffirmation of its an 'Outperform' rating by the Royal Bank of Canada. Work towards
Global Health Equity is apparent in their initiatives to advance health equity in the U.S and their plans to extend the VERMOX® Donation Program through 2030. JNJ was also listed amongst
Fortune's Most Innovative Companies and
World's most admired companies. Johnson & Johnson reported respectable quarterly earnings, while also being involved in the sales and acquisitions of assets like Kenvue and Shockwave Medical. The company continues to innovate in areas like AI for surgery in association with Nvidia, however experienced a dip in the stock value recently.
Johnson Johnson JNJ News Analytics from Thu, 20 Jul 2023 07:00:00 GMT to Sun, 19 May 2024 10:39:34 GMT -
Rating 3
- Innovation 5
- Information 8
- Rumor -2
